Patents Represented by Attorney, Agent or Law Firm Arvie J. Anderson
  • Patent number: 7125871
    Abstract: Compounds of the formula (I) in which R1, R2 and X1 have the meanings given in the specification, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: October 24, 2006
    Assignee: Eli Lilly and Company
    Inventors: Ivan Collado Cano, Jesus Ezquerra-Carrera, Alicia Marcos Liorente, Luisa Maria Martin-Cabrejas, James Allen Monn
  • Patent number: 7081481
    Abstract: Compounds of the formula (I) in which: R1 is (CH2)nY; n is 1 or 2; Y is NHSO2R2 or X1—W—X2—R3; X1 is O or NH; W is C?O, C?S, C?NH, or SO2; X2 is O or NH, provided that X1 and X2 are not both O; R2 is C1-10 alkyl; C2-10 alkenyl; C2-10 alkynyl; aryl; aryl-C1-10 alkyl; aryl-C2-10 alkenyl; aryl-C2-10alkynyl; C3-8 cycloalkyl or C3-8-cycloalkyl-C1-10 alkyl; and R3 is hydrogen, C1-10alkyl; C2-10 alkenyl; C2-10 alkynyl; aryl; aryl-C1-10 alkyl; aryl-C2-10 alkenyl; aryl-C2-10 alkynyl; C3-8 cycloalkyl; or C3-8-cycloalkyl-C1-10 alkyl; or a salt or ester thereof, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: July 25, 2006
    Assignee: Eli Lilly and Company
    Inventors: Ivan Collado-Cano, Maria Rosario Gonzalez-Garcia, Beatriz López De Uralde-Garmendia
  • Patent number: 7038077
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: May 2, 2006
    Assignee: Eli Lilly and Company
    Inventors: Anne Hollins Dantzig, James Allen Monn, Stephanie Ann Sweetana, Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Marc Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Carlos Montero Salgado, Concepcion Pedregal-Tercero
  • Patent number: 7037932
    Abstract: There is provided a heretoaryloxy 3-substituted propanamine compound of formula (I): wherein A is selected from —O— and —S—; X is selected from phenyl optionally substituted with up to 5 substituents selected from halo, C1–C4 alkyl and C1–C4 alkoxy, and thienyl optionally substituted with up to 3 substituents selected from halo and C1–C4 alkyl; Y is selected from benzothienyl, indolyl and benzofuranyl, optionally substituted with up to 5 substituents selected from halo, C1–C4 alkyl, C1–C4 alkoxy, nitro, acetyl and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1–C4 alkyl; R1 and R2 are each independently H or C1–C4 alkyl; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: May 2, 2006
    Assignee: Eli Lilly and Company
    Inventors: Peter Gallagher, Richard Edmund Rathmell, Maria Ann Fagan
  • Patent number: 6846830
    Abstract: Use of compounds of the formula (I) where A, E, R1, R2, p and q have the meanings given in the specification are GluR6 antagonists useful for the treatment of disorders of the central nervous system.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: January 25, 2005
    Assignee: Eli Lilly and Company
    Inventors: Stephen Richard Baker, David Bleakman, Carlos Lamas-Peteira
  • Patent number: 6800651
    Abstract: The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: October 5, 2004
    Assignee: Eli Lilly and Company
    Inventors: Darrell Stephen Coleman, Gunnar Erik Jagdmann, Kirk Willis Johnson, Michael Parvin Johnson, Thomas Hallett Large, James Allen Monn, Darryle Darwin Schoepp, Thomas Charles Britton, Steven Scott Henry, Joseph Patrick Tizzano
  • Patent number: 6620837
    Abstract: This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of defined compounds of formula (I) as thrombin inhibitors.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: September 16, 2003
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, John Eldon Toth, Kumiko Takeuchi, Todd Johnathan Kohn, Jolie Anne Bastian
  • Patent number: 6596756
    Abstract: A method of using N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine to treat persistent pain.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: July 22, 2003
    Assignee: Eli Lilly and Company
    Inventors: David Joel Goldstein, Smriti Iyengar, Rosa Marie Ademe Simmons
  • Patent number: 6541499
    Abstract: The invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts, as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: April 1, 2003
    Assignee: Eli Lilly and Company
    Inventors: Jolie A Bastian, Nickolay Y Chirgadze, Michael L Denney, Matthew J Fisher, Robert J Foglesong, Richard W Harper, Mary G Johnson, Valentine J Klimkowski, Ho-Shen Lin, Michael P Lynch, Jefferson R McCowan, Shawn C Miller, Jeffrey T Mullaney, Michael E Richett, Daniel J Sall, Gerald F Smith, Kumiko Takeuchi, Jennifer M Tinsley, Michael R Wiley, Minsheng Zhang
  • Patent number: 6504052
    Abstract: Compounds of the formula (I) in which R1 is C1-10 allyl; C2-10 alkenyl; C2-10 alkynyl; phenyl-C2-10 alkyl or phenyl-C2-10 alkenyl; and salts and esters thereof, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: January 7, 2003
    Assignee: Eli Lilly and Company
    Inventors: Ivan Collado Cano, Concepcion Pedregal Tercero, Alicia Marcos Llorente
  • Patent number: 6498180
    Abstract: Compounds of formula (I) in which R1 is halo-C1-10 alkyl; halo-C2-10 alkenyl; or (CH2)nY in which n is 1 or 2 and Y is OH, CN, N3, OR3, SH, S(O)pR4, S(O)3H, NH2, NHR5, NR6R7, NHCOR8, NO2, CO2H, CONHR9, 1H-tetrazol-5-yl, 5-phenyltetrazol-2-yl or PO3H2; R3, R5, R6, R7, R8 and R9 are each selected independently from C1-4 alkyl, aryl and aryl-C1-4 alkyl; R4 is selected from C1-4 alkyl, aryl, aryl-C1-4 alkyl, and 1H-tetrazol-5-yl, carboxy-(1-4C)alkyl and 1H-tetrazol-5-yl-C1-4 alkyl; and p is 0, 1, 2 or 3; or a salt or ester thereof, provided that R1 is not methoxymethyl, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: December 24, 2002
    Assignee: Eli Lilly and Company
    Inventors: Ivan Collado Cano, Concepcion Pedregal Tercero, Alicia Marcos Llorente, Beatriz Lopez de Uralde Garmendia, Maria Rosario Gonzalez Garcia, Ana Belen Bueno Melendo
  • Patent number: 6448422
    Abstract: This application relates to a novel compound of formula I, as defined herein, processes and intermediates for its preparation and the use of the compound of formula I as a substrate for a pharmaceutical screen.
    Type: Grant
    Filed: July 3, 2000
    Date of Patent: September 10, 2002
    Assignee: Eli Lilly and Company
    Inventors: Patrick Irving Eacho, Patricia Sue Foxworthy-Mason, Richard Waltz Harper, Ho-Shen Lin, Jose Eduardo Lopez, Michael Enrico Richett
  • Patent number: 6391901
    Abstract: This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of defined compounds of formula I as thrombin inhibitors.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: May 21, 2002
    Assignee: Eli Lilly and Company
    Inventors: Nickolay Y Chirgadze, Michael L Denney, Matthew J Fisher, Robert J Foglesong, Richard W Harper, Mary G Johnson, Ho-Shen Lin, Michael P Lynch, Jefferson R McCowan, Shawn C Miller, Alan D Palkowitz, Michael E Richett, Daniel J Sall, Gerald F Smith, Kumiko Takeuchi, Minsheng Zhang
  • Patent number: 6359136
    Abstract: This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: March 19, 2002
    Assignee: Eli Lilly and Company
    Inventors: Jolie Ann Bastian, Matthew Joseph Fisher, Richard Waltz Harper, Ho-Shen Lin, Jefferson Ray McCowan, Daniel Jon Sall, Gerald Floyd Smith, Kumiko Takeuchi, Michael Robert Wiley, Minsheng Zhang
  • Patent number: 6288105
    Abstract: This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: September 11, 2001
    Assignee: Eli Lilly and Company
    Inventors: Nickolay Y Chirgadze, Matthew J Fisher, Richard W Harper, Ho-Shen Lin, Jefferson R McCowan, Alan D Palkowitz, Daniel J Sall, Gerald F Smith, Kumiko Takeuchi, Minsheng Zhang
  • Patent number: 6284756
    Abstract: This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: September 4, 2001
    Assignee: Eli Lilly and Company
    Inventors: Nickolay Y Chirgadze, Richard W Harper, Todd J Kohn, Ho-Shen Lin, Jefferson R McCowan, Alan D Palkowitz, Daniel J Sall, Gerald F Smith, Kumiko Takeuchi, Michael R Wiley, Minsheng Zhang
  • Patent number: 6271227
    Abstract: This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.
    Type: Grant
    Filed: January 24, 2000
    Date of Patent: August 7, 2001
    Assignee: Eli Lilly and Company
    Inventors: Nickolay Y Chirgadze, Matthew J Fisher, Richard W Harper, Ho-Shen Lin, Jefferson R McCowan, Alan D Palkowitz, Michael E Richett, Daniel J Sall, Gerald F Smith, Kumiko Takeuchi, Minsheng Zhang
  • Patent number: 6268507
    Abstract: Compounds of the formula in which R1 and R2 are as defined in the specification, and non-toxic metabolically labile ester and amides thereof are useful as modulators of metabotropic glutamate receptor function.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: July 31, 2001
    Assignee: Eli Lilly and Company
    Inventors: Steven Marc Massey, James Allen Monn, Matthew John Valli
  • Patent number: 6265416
    Abstract: This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: July 24, 2001
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Matthew Joseph Fisher, Richard Waltz Harper, Ho-Shen Lin, Jefferson Ray McCowan, Daniel Jon Sall, Gerald Floyd Smith, Kumiko Takeuchi, Michael Robert Wiley, Minsheng Zhang
  • Patent number: 6251921
    Abstract: This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula I.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: June 26, 2001
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Nickolay Yuri Chirgadze, Michael Lyle Denney, Matthew Joseph Fisher, Robert James Foglesong, Richard Waltz Harper, Mary George Johnson, Valentine Joseph Klimkowski, Todd Jonathan Kohn, Ho-Shen Lin, Michael Patrick Lynch, Jefferson Ray McCowan, Alan David Palkowitz, Michael Enrico Richett, Daniel Jon Sall, Gerald Floyd Smith, Kumiko Takeuchi, Jennifer Marie Tinsley, Minsheng Zhang